Clinical cancer research : an official journal of the American Association for Cancer Research 2021 May 14
Doxorubicin-Dexrazoxane from Day 1 for Soft-tissue Sarcomas: The Road to Cardioprotection.
ABSTRACT
Doxorubicin cardiac toxicity is widely misunderstood, largely preventable, and starts with the first dose. This article reviews the history of doxorubicin cardiac toxicity and strategies for minimizing it. Dexrazoxane cardioprotection can safely be initiated on day 1 without compromising antitumor activity, allowing doxorubicin administration beyond the reported maximum lifetime dose..
Related Questions
New answer by at Maria Fareri Children’s Hospital (September 8, 2023)
In planning for treatment for your patient, you might consider the following articles.
Anninga et al., PMID 21703851 - Of cisplatin, ifosfamide, doxorubicin, methotrexate, an...